The human BTN2A1, BTN3A1, BTN3A2, and BTN3A3 are emerging as key regulators of non-conventional Vγ9Vδ2 T cells, which are important effectors against selected microbial infections and cancers and have been shown to correlate with improved patient outcome when infiltrating tumoral tissue (73–85). Here, BTN2A1 is linked to cancer.